Tag: GlobeNewswire

ATHENS, Greece, Oct. 05, 2026 (GLOBE NEWSWIRE) — TEN Ltd. (NYSE: TEN) (“TEN” or the “Company”), a leading diversified tanker and LNG operator, today announced that its Board of Directors declared the regular quarterly cash dividend of approximately $0.59375 per share for its Series F Cumulative Redeemable Perpetual Preferred Shares (the “Series F Preferred Shares”; NYSE: TENPRF).

The dividend on the Series F Preferred Shares is for the period from the most recent dividend payment date on July 30, 2026, through October 29, 2026.

The dividend on the Series F Preferred Shares will be paid on October 30, 2026, to all holders of record of Series F Preferred Shares as of October 27, 2026. Dividends on the Series F Preferred Shares are payable quarterly in arrears on the 30^th day (unless the 30^th falls on a weekend or public holiday, in which case the payment date is moved to the next business day) of January, April, July and October of each year, when, as and if declared by TEN’s board of directors. This is the 33^rd dividend on the Series F Preferred Shares since their commencement of trading on the New York Stock Exchange.

TEN has 6,747,147 Series F Preferred Shares outstanding as of the date of this press release.

ABOUT TEN Ltd.
Founded in Bermuda in 1993 and celebrating 33 years as a public company, 24 of which on the NYSE, TEN is one of the first and most established public shipping companies in the world. TEN’s diversified pro-forma energy fleet currently consists of 80 vessels, totaling approx. 10.4 million dwt.

ABOUT FORWARD-LOOKING STATEMENTS
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those predicted by such forward-looking statements. TEN undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For further information, please contact:

Company
Tsakos Energy Navigation Ltd.
George Saroglou
President & COO
+30210 94 07 710
gsaroglou@tenn.gr

Investor Relations / Media
Capital Link, Inc.
Nicolas Bornozis
Markella Kara
+212 661 7566
ten@capitallink.com

NESS ZIONA, Israel, Oct. 05, 2026 (GLOBE NEWSWIRE) — Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“Foresight” or the “Company”), an innovator in 3D perception systems, today announced that Eli Yoresh, the Company’s Chief Financial Officer, and Oren Bar-On, co-Chief Executive Officer of Foresight Automotive Ltd., will present at the LD Micro 20^th Annual Main Event Conference in Los Angeles, California on Tuesday, October 20, 2026, at 9:00 a.m. PT.

Management will be available on-site for one-on-one meetings. To schedule a meeting, please contact LD Micro or Miri Segal at msegal@ms-ir.com.

A webcast of the presentation will be streamed live at the following link: https://ldmicroevents.com/.

About Foresight

Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) is a technology company developing advanced three-dimensional perception systems and cellular-based applications. Through its wholly owned subsidiaries, Foresight Automotive Ltd., Foresight Changzhou Automotive Ltd. and Eye-Net Mobile Ltd., Foresight develops both “in-line-of-sight” vision systems and “beyond-line-of sight” accident-prevention solutions. Foresight’s 3D perception systems include modules of automatic calibration and dense 3D point cloud that can be applied to different markets such as automotive, defense, autonomous driving, agriculture, heavy industrial equipment and unmanned aerial vehicles. Eye-Net Mobile develops next-generation vehicle-to-everything collision prevention solutions and smart automotive systems to enhance road safety and situational awareness for all road users in urban mobility environments. By leveraging cutting-edge artificial intelligence technology, advanced analytics, and existing cellular networks, Eye-Net’s innovative solution suite delivers real-time pre-collision alerts to all road users via smartphones and other smart devices within vehicles. For more information about Foresight and its wholly owned subsidiary, Foresight Automotive, visit www.foresightauto.com, follow @ForesightAuto1 on X, or join Foresight Automotive on LinkedIn.

About the LD Micro Main Event

The LD Micro 20th Annual Main Event will take place on October 19-21, 2026 at the Luxe Sunset Boulevard Hotel in Los Angeles, California. Registration begins at 2:00 PM PT on Monday, October 19, 2026, followed by keynote programming and a networking reception.

Company presentations will run from 9:00 a.m. PT to 4:00 p.m. PT on Tuesday, October 20 and Wednesday, October 21, 2026. The event will feature more than 100 public companies presenting to and participating in private meetings with investors. Wednesday’s program will conclude with the LD Micro Moneyball Afterparty.

LD Micro, a wholly owned subsidiary of Freedom U.S. Markets, LLC, was founded in 2006 with the sole purpose of being an independent resource in the micro-cap space. Through its dynamic, investor-driven conferences and curated company exposure, LD Micro has served as an invaluable asset to all those interested in discovering the next generation of great companies. For more information on LD Micro, visit www.ldmicro.com.

Investor Relations Contact:
Miri Segal-Scharia
CEO
MS-IR LLC
msegal@ms-ir.com

The Phase 1/2 ABILITY-1 Clinical Trial is evaluating MDNA11 in expansion cohorts comprised of patients with advanced and metastatic gastrointestinal, endometrial, and melanoma cancers

Selected as one of the Top 150 Abstracts at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting

TORONTO and HOUSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superkines for targeting cancer and autoimmune disease, today announced that an abstract reporting topline data from the Phase 1/2 study of MDNA11 has been selected for oral presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting.

Details of the oral presentation are as follows:
Abstract Number: 517
Presentation Type: Oral Presentation
Presentation Date: Saturday, November 7, 2026
Presentation Time: 4:30-4:45 p.m. MST
Session: Oral Session 3, 3:30-4:50 p.m. MST
Location: Phoenix Convention Center, Room 301D, Phoenix, Arizona

Title: “MDNA11 Demonstrates Clinical Activity as Monotherapy and in Combination with Pembrolizumab in Biomarker-Enriched Gastrointestinal Malignancies, Including ICI-Refractory Disease.”

About Medicenna Therapeutics
Medicenna is a clinical-stage immunotherapy company developing engineered cytokine therapies designed to selectively engage the immune system to treat cancer. The Company’s most advanced program, bizaxofusp (formerly MDNA55), is a targeted IL-4 Empowered Superkine that has been evaluated in more than 130 patients across five clinical trials, including a Phase 2b study in recurrent glioblastoma. Bizaxofusp has received Fast Track designation from the FDA and Orphan Drug designation in the United States and Europe. Medicenna is also advancing MDNA11, a long-acting IL-2 Superkine designed to selectively activate cancer-fighting immune cells, which is currently being evaluated in the Phase 1/2 ABILITY-1 study and the Phase 1b NEO-CYT study. The Company is also developing MDNA113, a targeted PD-1 x IL-2 bifunctional immunotherapy for solid tumors, and MDNA209, an antagonist of CD122 blocking IL-2/IL-15 signaling, using its proprietary BiSKIT and T-MASK platforms.

For more information, please visit www.medicenna.com, and follow us on X and LinkedIn.

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, express or implied statements regarding the future operations of the Company, estimates, plans, strategic ambitions, partnership activities and opportunities, objectives, expectations, opinions, forecasts, projections, guidance, outlook or other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expect”, “believe”, “seek”, “potentially” and similar expressions. and are subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the risks detailed in the latest annual information form of the Company and in other filings made by the Company with the applicable securities regulators from time to time in Canada.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date hereof and except as required by law, we do not intend and do not assume any obligation to update or revise publicly any of the included forward-looking statements.

This news release contains hyperlinks to information that is not deemed to be incorporated by reference in this new release.

Investor and Company Contact
Daniel Scarr
Director, Corporate Development
Medicenna Therapeutics
ir@medicenna.com 

CALGARY, Alberta, Oct. 05, 2026 (GLOBE NEWSWIRE) — Canoe Financial is proud to announce a new sponsorship partnership with Canadian Olympic Gold Medallist and World Champion canoeist Katie Vincent, one of Canada’s most accomplished athletes and a leading figure in the sport of canoe sprint. The partnership will extend through the 2028 Olympic cycle and will feature a national marketing campaign built around the principles that define both Vincent’s athletic journey and Canoe Financial’s investment philosophy: Discipline compounds. Performance is earned.

As Canada’s premier canoe sprint athlete, Vincent has established herself among the world’s elite through years of dedication, preparation, and relentless commitment to excellence. Her career includes Olympic gold and bronze medals, world championship titles, and multiple world records, achievements built through a disciplined process long before race day.

The partnership reflects a natural alignment between Vincent’s approach to athletic performance and Canoe Financial’s approach to investing. Both recognize that success is rarely defined by a single moment. It is the result of a disciplined process, repeated consistently over time.

“Katie’s story is about more than winning medals,” said Darcy Hulston, President and Chief Executive Officer of Canoe Financial. “Her success is built on the same beliefs that guide our business every day. Driven by process. Discipline compounds. Performance is earned. Those beliefs are at the heart of everything we do for our investors, and Katie is an inspiring example of what can be achieved when you commit to them over the long term.”

The sponsorship also represents a uniquely authentic connection between Canoe Financial and the sport of canoeing. As Vincent competes on the world stage, Canoe Financial will support her journey while celebrating the values of perseverance, preparation, and excellence that resonate with Canadians from coast to coast.

About Canoe Financial
Canoe Financial is one of Canada’s fastest growing independent mutual fund companies managing nearly $25 billion in assets across a diversified range of award-winning investment solutions. Founded in 2008, Canoe Financial is an employee-owned investment management firm focused on building financial wealth for Canadians. Canoe Financial has a significant presence across Canada, including offices in Calgary, Toronto and Montreal.

Contact
Investor Relations
1–877–434–2796
info@canoefinancial.com

Commissions, trailing commissions, management fees and expenses all may be associated with mutual fund investments. Please read the prospectus before investing. Mutual funds are not guaranteed, their values change frequently and past performance may not be repeated.

Coop Pank AS (the Bank) announces that during the period 28.09.2026 – 04.10.2026, it has acquired the company’s own shares on the Nasdaq Tallinn Stock Exchange as follows:

Date	Aggregated volume (pcs)	Weighted average price per day (EUR)
28.09.2026	9,264	2.31000000
29.09.2026	9,264	2.30500000
30.09.2026	3,516	2.29000000
01.10.2026	2,742	2.30000000

Bank is acquiring its own shares based on the resolution of the company’s general meeting of shareholders held on 8 April 2026, and under the conditions decided by the Supervisory Board and Management Board. Summary data of the acquisitions will be disclosed no later than on the seventh trading day after the transaction and will be made available to the Financial Supervision and Resolution Authority, via the Nasdaq Tallinn system, and on Coop Bank´s investor website.

Additional information:
Paavo Truu
CFO
Phone: 5160 231
E-mail: paavo.truu@cooppank.ee

Coop Pank, based on Estonian capital, is one of the five universal banks operating in Estonia. The bank has 239,100 clients who use everyday banking services. Coop Pank uses the synergy created between retail trade and banking and brings everyday banking solutions closer to people. The majority shareholder of the Bank is a domestic retail chain Coop Eesti, the sales network of which comprises over 330 stores.

AS Tallinna Sadam (hereinafter Tallinna Sadam) and TT-Line GmbH (hereinafter TT-Line) have signed an agreement for the operation of a vessel on the Muuga (Estonia)–Vuosaari (Finland) route. The route will be served by a ro-pax ferry with around 2 000 freight lanemeters and a restaurant/café, a passenger lounge and other facilities for passengers and truckdrivers as well as cabins. The vessel used is intended to be announced in November. The vessel is expected to start operating on the route during the first quarter of 2027, with the exact launch date to be confirmed. 

The Muuga–Vuosaari ferry connection is of strategic importance for freight transport between Estonia and Finland. It provides logistics and transport companies with a fast maritime route and helps divert trucks and trailers away from the city centres of Tallinn and Helsinki. The connection supports the competitiveness of Estonia’s export-oriented economy by improving companies’ access to Finnish and, more broadly, Nordic markets. At the same time, it strengthens the position of Estonia and Muuga harbour as a key north-south transport and transit corridor, linking Finland to the Baltic states and, subsequently, to Central and Southern Europe.

The regular ferry route between the cargo harbours operated by the ports of Tallinn and Helsinki was launched in 2017 and has been served by both Tallink and Eckerö Line. Currently, the route is operated by Eckerö Line with the vessel Finbo Cargo.

“Freight volumes on the Muuga–Vuosaari route have grown steadily over the years and are now approaching the limits of what can be handled with a single vessel. This clearly demonstrates market demand for additional capacity and more frequent departures. The addition of a second operator will provide customers with greater choice and flexibility, strengthen the reliability of the connection and support further growth in trade between Estonia and Finland,” said Rene Pärt, Member of the Management Board of Tallinna Sadam.

The agreement will contribute to the port’s revenues through vessel call, cargo and passenger fees, while enabling more efficient use of existing infrastructure.

TT-Line is a family-owned shipping company established in 1962 in Germany.  Its fleet consists of 9 ro-pax vessels. The company’s core business is the transport of passengers, passenger vehicles and freight, connecting Germany,Sweden, Poland and Lithuania and serving routes that include the ports of Travemünde, Rostock, Trelleborg, Karlshamn, Świnoujście and Klaipėda.

Tallinna Sadam is one of the largest cargo- and passenger port complexes in the Baltic Sea region. In addition to passenger and freight services, Tallinna Sadam group also operates in shipping business via its subsidiaries – OÜ TS Laevad provides ferry services between the Estonian mainland and the largest islands, and OÜ TS Shipping charters its multifunctional vessel Botnica for icebreaking and offshore services in Estonia and projects abroad. Tallinna Sadam group is also a shareholder of an associate AS Green Marine, which provides waste management services.

Additional information:

Angelika Annus
Head of Investor Relations
Tel. +372 5649 6230
angelika.annus@ts.ee

WASHINGTON and NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) — The Carlyle Group Inc. (NASDAQ: CG) announced today that it will release financial results for the third quarter 2026 on Thursday, November 5, 2026, and host a conference call at 8:30 a.m. EST. The conference call will be available via public webcast from the Events & Presentations section of ir.carlyle.com and a replay will also be available after the call’s completion.

Chief Executive Officer Harvey Schwartz, Chief Financial Officer Justin Plouffe, and Head of Public Investor Relations Daniel Harris, will review the results during the call.

The earnings release will be available through all Carlyle channels, including the Earnings Releases section of ir.carlyle.com and the firm’s X and LinkedIn accounts.

About Carlyle

Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit, and Carlyle AlpInvest. With $485 billion of assets under management as of June 30, 2026, Carlyle’s purpose is to connect people, ideas, and capital to fuel growth for companies and performance for investors. Carlyle employs more than 2,500 people in 28 offices across four continents.

Contacts
Public Investor Relations
Daniel Harris
+1 (212) 813-4527
daniel.harris@carlyle.com

Media
Brittany Bensaull
+1 (212) 813-4839
brittany.bensaull@carlyle.com 

SAN DIEGO, Oct. 05, 2026 (GLOBE NEWSWIRE) — LPL Financial LLC announced today that Praxis Financial Partners advisors Scott Christian, CFP®, Cecil Loyd, CIMA®, Jay Gentry, CIMA® and Matt Dion have joined LPL Financial’s broker-dealer and Registered Investment Advisor (RIA) platform. The team reported serving approximately $1.1 billion in advisory, brokerage and retirement plan assets* and joins LPL from Wells Fargo Advisors Financial Network.

Based in Alpharetta, Ga., Praxis Financial Partners is a planning-focused wealth management practice serving business owners, corporate retirees, successful executives and multigenerational families across 24 states. The firm traces its roots to 2013, when Christian and Loyd launched Praxis after working together for decades. The name “Praxis,” derived from the Greek word for “process,” reflects the team’s planning-based philosophy. Gentry joined the practice in 2020 after 20 years in asset management distribution, while Dion joined in 2024 after 15 years as an advisor.

Today, the practice combines the experience of four advisors with a tenured support team that includes Jody Smith, Zac Hirschler, Ashlyn Presley, Ellen Rick, Seleena Harris and Parvathy Eashwaran. The team credits its service model as a key reason for its client retention, referral growth and longstanding multigenerational relationships.

“We’ve always believed that good financial advice begins with understanding what matters most to each client,” Christian said. “We take the time to learn their goals, priorities and risk tolerance, then develop customized strategies supported by an ongoing review process. Every client is different, and our objective is to create solutions tailored to their unique circumstances rather than relying on a one-size-fits-all approach.”

Collaboration is central to the firm’s client experience. The advisors regularly work together on client strategies and maintain weekly investment committee meetings, where portfolio decisions, market developments and investment opportunities are evaluated collectively. By managing a significant portion of client assets in-house, the team provides clients with direct access to the advisors responsible for investment decisions and portfolio construction.

“The foundation of our business is service,” Gentry said. “Many of our client relationships span multiple generations, and that continuity is made possible by an incredible team of professionals who care deeply about the people we serve. Our clients know they can count on the same familiar faces year after year, and that’s something we are incredibly proud of.”

Why Praxis Financial Partners Chose LPL

As the firm evaluated its next chapter, the advisors sought a partner that would provide greater flexibility, advanced planning capabilities and access to emerging technology.

“The financial advice landscape continues to evolve rapidly, and we wanted a partner that allows us to stay ahead of those changes,” Christian said. “LPL’s open architecture platform gives us the freedom to build the wealth management ecosystem we believe best serves our clients. The planning tools, flexibility and ability to create our own technology stack will help us continue delivering exceptional service while positioning the firm for future growth.”

Dion added, “We were looking for a partner committed to innovation and focused on helping advisors deliver greater value. LPL’s technology and resources will enable us to continue enhancing the client experience while maintaining the personalized service our clients expect.”

The team also valued LPL’s ability to support its long-term independence strategy. After evaluating more than a dozen firms, Praxis selected LPL because it offered the resources and scale the advisors were seeking while allowing them to maintain ownership of their business and preserve future succession and continuity options.

LPL Chief Growth Officer Marc Cohen said, “Scott, Cecil, Jay and Matt have built Praxis Financial Partners with a clear sense of purpose. Even the firm’s name speaks to their disciplined, planning-first approach, and that philosophy comes through in everything from their collaborative investment process to the multigenerational relationships they’ve cultivated over the years. They’ve created a business that balances deep technical expertise with a genuine commitment to understanding what matters most to each client. We are honored they chose LPL for this next chapter and look forward to supporting Praxis Financial Partners as they continue evolving their business while staying true to the values that have driven their success.”

Related

Advisors, learn how LPL Financial can help take your business to the next level.

About LPL Financial

LPL Financial Holdings Inc. (Nasdaq: LPLA) is among the fastest growing wealth management firms in the U.S. As a leader in the financial advisor-mediated marketplace, LPL supports more than 32,000 financial advisors and the wealth management practices of approximately 1,100 financial institutions, servicing and custodying approximately $2.6 trillion in brokerage and advisory assets on behalf of approximately 8 million Americans. The firm provides a wide range of advisor affiliation models, investment solutions, fintech tools and practice management services, ensuring that advisors and institutions have the flexibility to choose the business model, services, and technology resources they need to run thriving businesses. For further information about LPL, please visit www.lpl.com.

Securities and advisory services offered through LPL Financial LLC (“LPL Financial”), a registered investment advisor and broker-dealer, member FINRA/SIPC. Praxis Financial Partners and LPL Financial are separate entities.

Throughout this communication, the terms “financial advisors” and “advisors” are used to refer to registered representatives and/or investment advisor representatives affiliated with LPL Financial.

We routinely disclose information that may be important to shareholders in the “Investor Relations” or “Press Releases” section of our website.

*Value approximated based on asset and holding details provided to LPL from end of year, 2025.

Media Contact: 
Media.relations@LPLFinancial.com  

Tracking #1175084

LOS ANGELES, CA, Oct. 05, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in AL Amyloidosis, today announced that it will present at the 45th Annual J.P. Morgan Healthcare Conference being held January 11-14, 2027 in San Francisco, CA.

A link to access the replay, when available, will be posted to the Immix website on the Presentation & Events page under the Investors section.

About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a proprietary CD3ζ, CD8 hinge and binder “digital filter” designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a potentially registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.

Contacts
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com 

Company Contact
irteam@immixbio.com 

Companies to Meet Formally with FDA’s Center for Veterinary Medicine on November 19th for Pre-Submission Conference; U.S. Manufacturing Strategy Underway to Support Potential 2027 Veterinary Product Launch

FORT LAUDERDALE, Fla., Oct. 05, 2026 (GLOBE NEWSWIRE) — Endovia Health Sciences, Inc. (“Endovia” or the “Company”) (NYSE American: EDVA), in association with Lupvindol BioSciences (“Lupvindol”), today announced that the U.S. Food and Drug Administration’s (“FDA”) Center for Veterinary Medicine has determined that the proposed use of CannEpil^®, an investigational cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”) oral solution, for the control of pain associated with bone cancer in dogs qualifies as a “minor use” under the Minor Use and Minor Species (“MUMS”) program.

The FDA determination establishes CannEpil’s eligibility to pursue the conditional approval pathway for this proposed indication. The FDA further determined that the minor-use status will be maintained through approval of the applicable New Animal Drug Application (“NADA”).

Under the MUMS framework, qualifying new animal drugs may be eligible for conditional approval which is a regulatory pathway designed to facilitate earlier availability of therapies for uncommon diseases and conditions in animals. Conditional approval requires satisfaction of applicable FDA requirements, including safety and manufacturing standards and a reasonable expectation of effectiveness, while allowing additional effectiveness data required for full approval to be collected following conditional approval.

Endovia and Lupvindol are scheduled to meet formally with the FDA on November 19, 2026, for a Pre-Submission Conference to discuss and align with the FDA on the proposed CannEpil^® development program, including the studies, manufacturing requirements and regulatory submissions necessary to pursue conditional approval.

In parallel with the regulatory program, Endovia and Lupvindol are actively sourcing and finalizing U.S.-based manufacturing capabilities for CannEpil^®. This work is intended to establish a scalable, FDA-compliant domestic supply chain capable of supporting the clinical and regulatory program and, subject to receipt of the necessary regulatory approvals, a potential commercial launch for veterinary use in 2027.

“This determination represents an important regulatory milestone for CannEpil^® and provides greater clarity around the pathway we are pursuing with the FDA,” said Brady Cobb, Interim Chief Executive Officer of Endovia Health Sciences. “Importantly, we are not waiting to begin preparing for commercialization. Alongside Lupvindol, we are advancing our FDA development program while simultaneously working to establish U.S. manufacturing and supply capabilities that can support a potential veterinary launch in 2027, subject to regulatory approval.”

Cobb continued, “We believe CannEpil has the potential to demonstrate what a science-driven, federally regulated cannabinoid medicine can look like in the United States. Our veterinary program gives us an opportunity to address a serious unmet need for dogs suffering from cancer-related pain while building the regulatory, manufacturing and scientific infrastructure that we believe can support the broader development of CannEpil.”

The MUMS conditional approval pathway was established to encourage development of new animal drugs for uncommon conditions affecting relatively small populations. Following conditional approval, a sponsor may legally market a qualifying animal drug while continuing to collect the additional effectiveness data necessary to support full FDA approval, subject to applicable statutory and regulatory requirements and annual FDA renewal.

CannEpil^® remains an investigational new animal drug and has not been approved or conditionally approved by the FDA. The Company’s anticipated development timelines, including a potential 2027 commercial launch, remain subject to FDA review, successful completion of applicable regulatory requirements, manufacturing readiness and other factors.

About CannEpil^®

CannEpil^® is a proprietary cannabinoid-based oral formulation containing cannabidiol (CBD) and tetrahydrocannabinol (THC). Endovia and Lupvindol BioSciences are advancing CannEpil through the FDA’s Center for Veterinary Medicine for the proposed control of pain associated with bone cancer in dogs.

The veterinary development program is part of Endovia’s broader strategy to develop cannabinoid-based therapeutics through established federal regulatory pathways and to build a platform capable of supporting additional veterinary and human therapeutic applications, subject to applicable statutory and regulatory requirements.

About Endovia Health Sciences

Endovia Health Sciences, Inc. (NYSE American: EDVA) is a cannabinoid health sciences company focused on building a diversified platform across pharmaceutical development, FDA-regulated human and veterinary therapeutics, international pharmaceutical commercialization and cannabinoid-based wellness products.

About Lupvindol Biosciences Ltd.

Lupvindol Biosciences Ltd. is a pharmaceutical and bioscience development company with expertise in cannabinoid-based therapeutics and U.S. FDA regulatory pathways. The company is led by Hunter Land, Ph.D., whose experience includes participation in the development of Epidiolex^® and Sativex^® at GW Pharmaceuticals.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform act of 1995 including statements regarding the development and commercialization of CannEpil^®; obtaining a manufacturing source, and a potential commercial veterinary launch in 2027.

Forward-looking statements are based on current expectations, estimates, projections and assumptions and involve risks and uncertainties that could cause actual results to differ materially. Some or all of these risks may not occur. These risks include the Company’s ability to obtain additional financing; the development of and obtaining regulatory authorization for and commercialize CannEpil^® for veterinary use, the results of any clinical trials, the availability of raw materials, the ability to obtain a manufacturer to meet our needs on a financially viable basis, ; maintaining its rights under applicable license agreements; the enactment, implementation or impact of proposed legislation or regulatory initiatives; ability to meet competition from both CBD and conventional pharmaceuticals products ,our ability to successfully execute commercialization or strategic-partnering arrangements, and the risk that that the market or demand for any resulting product we seek to commercialize in the future could be less than expected or projected.

Additional risks are described in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and the final prospectus filed pursuant to Rule 424(b)(3) on August 28, 2026.

Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise any such statements whether as a result of new information, future events or otherwise, except as required by applicable law.

Investor Contact
Endovia Health Sciences
investors@endoviasciences.com

Media Contact
Angela Gorman
AMWPR
angela@amwpr.com
917-348-0083